Neumora plans clinical trials, data readouts through 2026

Neumora Therapeutics Inc. (NASDAQ: NMRA) outlined its 2026 pipeline strategy, including planned clinical data readouts and new trial initiations across multiple therapeutic programs.

The company plans to increase enrollment in its KOASTAL-2 and KOASTAL-3 studies by up to 25% beyond the original target of 332 participants each. Neumora expects to report joint topline data for both studies in the second quarter of 2026, evaluating navacaprant for major depressive disorder.

The company plans to initiate a Phase 1 clinical program for NMRA-215 in the first half of 2026, evaluating both monotherapy and combination therapy for obesity treatment. Weight loss data from NMRA-215 treatment is expected around the end of 2026.

Neumora reported that NMRA-511 met the goal of its Phase 1b study in January 2026, demonstrating what the company described as a clinically meaningful effect on the Cohen-Mansfield Agitation Inventory total score in patients with Alzheimer's disease agitation. The oral vasopressin 1a receptor antagonist showed no reports of somnolence or sedation in the study.

The company expects to provide an update on its M4 positive allosteric modulator franchise in mid-2026, which includes Phase 1 clinical studies for NMRA-898 and NMRA-861.

Neumora stated its cash, cash equivalents and marketable securities are expected to support operations into the third quarter of 2027. The clinical-stage biopharmaceutical company focuses on developing treatments for neuropsychiatric disorders and neurodegenerative diseases.

You May Also Be Interested In